Proteostasis Therapeutics Stock Price - PTI

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Proteostasis Therapeutics Inc PTI NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.06 3.64% 1.71 1.63 1.75 1.66 1.65 23:59:38
Bid Price Ask Price Spread Spread % News
1.70 1.72 0.02 1.16% 3 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,200 758,510 $ 1.71 $ 1,295,972 1,838,830 0.61 - 5.26
Last Trade Time Type Quantity Stock Price Currency
19:24:45 formt 100 $ 1.71 USD

Proteostasis Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 87.43M 51.13M $ -61.83M -1.60 - 50.58M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 1.10%

more financials information »

Proteostasis Therapeutics News

Loading Messages....

Latest PTI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PTI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.701.751.531.65840,8310.010.59%
1 Month1.972.071.531.781,207,169-0.26-13.2%
3 Months1.595.261.202.406,123,8280.127.55%
6 Months0.615.260.612.223,135,4121.10180.33%
1 Year3.935.260.612.012,305,801-2.22-56.49%
3 Years14.9116.670.613.941,438,203-13.20-88.53%
5 Years8.0020.630.614.171,108,806-6.29-78.63%

Proteostasis Therapeutics Description

Proteostasis Therapeutics Inc is a United States-based company engaged in the biotechnology industry. Its core operations comprise of discovery and development of therapeutics that treat diseases caused by an imbalance in protein biosynthesis process in the body. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics. Using this platform, it has identified a new class of small molecules and amplifiers that modulate proteins in the proteostasis network. The products under its development cycle include PTI-428, which is a lead amplifier of CFTR protein. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.